Cybin Inc., a clinical-stage neuropsychiatry company, has announced the issuance of U.S. patent 12,318,477, a significant advancement for its CYB004 program. This patent covers novel intramuscular formulations of DMT and related compounds, ensuring exclusivity for Cybin through 2040. The CYB004 program focuses on developing a deuterated DMT candidate for the treatment of generalized anxiety disorder (GAD), offering a promising new avenue for patients seeking rapid-acting and short-duration treatment options.
Doug Drysdale, CEO of Cybin, emphasized the importance of this patent as a validation of the CYB004 program's potential to revolutionize mental health care. With the compound currently in Phase 2 trials, expected to conclude by mid-2025, this patent underscores Cybin's commitment to addressing the unmet needs in mental health treatment through innovative psychedelic-based therapeutics.
Cybin's portfolio now includes over 90 granted patents and more than 230 pending applications, highlighting the company's leading position in the development of next-generation mental health therapies. The CYB004 program represents a critical component of Cybin's research pipeline, which also includes CYB003, a proprietary deuterated psilocybin analog for major depressive disorder, among other investigational compounds.
This development not only reinforces Cybin's pioneering role in the psychedelic and mental health sectors but also signals a broader shift towards the acceptance and integration of psychedelic-based treatments in mainstream medicine. The implications of this patent extend beyond Cybin, offering hope for millions of individuals suffering from GAD and potentially paving the way for new standards in mental health care.
